A solid understanding of the role of imaging and the surgical options in the setting of pediatric osteosarcoma can have a direct and positive effect on the care of affected patients. Osteosarcoma is the most common primary bone sarcoma in children. Imaging plays a pivotal role in diagnostic workup, surgical planning, and follow-up monitoring for possible disease relapse. Surviv...
Objective.: To seek predictors of therapeutic response to the interleukin (IL)-1 inhibitor anakinra in children with systemic-onset juvenile idiopathic arthritis (sJIA).Methods.: The clinical charts of all patients with sJIA who were newly treated with anakinra at our center between 2004 and 2017 were reviewed retrospectively. Predictors included baseline demographic, clinical, and laboratory variables as well as previous or concomitant therapies. The effectiveness of anakinra was assessed at 1 year after treatment start. Complete clinical response (CCR) was defined as absence of fever, physician’s global assessment ≤ 1, count of active joints ≤ 1, negative C-reactive protein, and ≥ 75% reduction of corticosteroid dose. According to the intention-to-treat principle, patients who had anakinra discontinued before 1 year for any reasons other than disease remission were classified as nonresponders. Statistics included univariate and multivariable analyses.Results.: Of the 62 patients included in the study, 24 (39%) met the criteria for CCR at 1 year, whereas 38 (61%) did not. On multivariable analysis, independent correlations with achievement of CCR were identified for shorter disease duration, lower active joint count, higher ferritin level, and greater activity of systemic manifestations. The area under the curve of the model was 0.83.Conclusion.: Our findings help to delineate the clinical profile of patients with sJIA who are more likely to benefit from IL-1 blockade. They also underscore the need for studies aimed at examining the therapeutic role of early IL-1 inhibition and to identify biomarkers predicting response to either IL-1 or IL-6 antagonists.
Chronic non-bacterial osteomyelitis (CNO) is an autoinflammatory bone disorder that usually involves long bone metaphyses of the lower extremities and can affect the clavicles, pelvis, mandible, sternum, and spine. The spine is recognized as a classic feature of CNO, but routine whole-body MRI with coronal-only STIR images may underreport its frequency. Dedicated sagittal spinal imaging is important not only in proving a multifocal process but also because vertebral height loss and vertebra plana in CNO can result in scoliosis and kyphosis. Aggressive treatment can prevent vertebral collapse and promote vertebral body height recovery. Spinal CNO typically involves the thoracic spine, is often multifocal, usually shows non-contiguous vertebral involvement, and demonstrates abnormal high T2W signal at the vertebral body and endplate destruction-sometimes as a spondylodiscitis. Importantly, in distinguishing it from other potential causes, CNO usually has no soft tissue mass. Treatment with pamidronate may result in a bone-in-bone appearance.